{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous Methylprednisolone\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To shorten the duration of the acute relapse To reduce the severity of current neurological deficits\n\n*   **Treatment:** Gastroprotection (e.g. Omeprazole)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To prevent gastric irritation and ulceration from high-dose steroids\n\n*   **Treatment:** Disease Modifying Therapy (e.g. Ocrelizumab, Natalizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Definitive diagnosis (MS vs NMOSD) is required to select the appropriate agent Pre-treatment screening (e.g., for latent infections) is required\n\n*   **Treatment:** Physiotherapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To address gait instability and ataxia To prevent falls and complications of immobility\n\n\ntreatments = [{\"treatment\": \"Intravenous Methylprednisolone\", \"timing\": \"Start Now\", \"reasons\": [\"To shorten the duration of the acute relapse\", \"To reduce the severity of current neurological deficits\"]}, {\"treatment\": \"Gastroprotection (e.g. Omeprazole)\", \"timing\": \"Start Now\", \"reasons\": [\"To prevent gastric irritation and ulceration from high-dose steroids\"]}, {\"treatment\": \"Disease Modifying Therapy (e.g. Ocrelizumab, Natalizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Definitive diagnosis (MS vs NMOSD) is required to select the appropriate agent\", \"Pre-treatment screening (e.g., for latent infections) is required\"]}, {\"treatment\": \"Physiotherapy\", \"timing\": \"Start Now\", \"reasons\": [\"To address gait instability and ataxia\", \"To prevent falls and complications of immobility\"]}]"
}